MX2009011856A - Oligomeros de cambio de division de receptores de la superfamilia tnf y su uso en tratamientos o enfermedades. - Google Patents

Oligomeros de cambio de division de receptores de la superfamilia tnf y su uso en tratamientos o enfermedades.

Info

Publication number
MX2009011856A
MX2009011856A MX2009011856A MX2009011856A MX2009011856A MX 2009011856 A MX2009011856 A MX 2009011856A MX 2009011856 A MX2009011856 A MX 2009011856A MX 2009011856 A MX2009011856 A MX 2009011856A MX 2009011856 A MX2009011856 A MX 2009011856A
Authority
MX
Mexico
Prior art keywords
treatment
splice switching
disease
ssos
tnf superfamily
Prior art date
Application number
MX2009011856A
Other languages
English (en)
Inventor
Peter L Sazani
Henrik Orum
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/010556 external-priority patent/WO2008051306A1/en
Priority claimed from US11/799,117 external-priority patent/US7785834B2/en
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Publication of MX2009011856A publication Critical patent/MX2009011856A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a oligonucleótidos de cambio de división u oligómeros de cambio de división (SSOs). Los SSOs preferidos de acuerdo con la presente invención dirigen el oxon 7 del pre-mARN TNFR1 (TNFRSF1A) o TNFR2 (TNFRSF1A), dando como resultado normalmente la producción de variantes TNFR que comprenden una eliminación en parte o de todo el exon 7, respectivamente. Los SSOs que dirigen el exon 7 se encuentran para dar como resultado una forma soluble del TNFR, que tiene un beneficio terapéutico para el tratamiento de enfermedades inflamatorias. Los SSOs están caracterizados porque son substancialmente incapaces o incapaces de reclutar RNaseH.
MX2009011856A 2007-05-01 2007-10-19 Oligomeros de cambio de division de receptores de la superfamilia tnf y su uso en tratamientos o enfermedades. MX2009011856A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2007/010556 WO2008051306A1 (en) 2006-10-20 2007-05-01 Soluble tnf receptors and their use in treatment of disease
US11/799,117 US7785834B2 (en) 2005-11-10 2007-05-01 Soluble TNF receptors and their use in treatment of disease
PCT/EP2007/061211 WO2008131807A2 (en) 2007-05-01 2007-10-19 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease

Publications (1)

Publication Number Publication Date
MX2009011856A true MX2009011856A (es) 2010-06-23

Family

ID=39929868

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009011856A MX2009011856A (es) 2007-05-01 2007-10-19 Oligomeros de cambio de division de receptores de la superfamilia tnf y su uso en tratamientos o enfermedades.
MX2012008375A MX346434B (es) 2007-05-01 2007-10-19 Oligómeros de cambio de empalme de receptores de la superfamilia tnf y su uso en el tratamiento de enfermedades.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012008375A MX346434B (es) 2007-05-01 2007-10-19 Oligómeros de cambio de empalme de receptores de la superfamilia tnf y su uso en el tratamiento de enfermedades.

Country Status (10)

Country Link
US (1) US20120142759A1 (es)
EP (1) EP2147103B1 (es)
JP (2) JP2010524476A (es)
KR (5) KR101531934B1 (es)
CN (2) CN101889086B (es)
AU (6) AU2007352163A1 (es)
CA (4) CA2684724A1 (es)
HK (2) HK1150850A1 (es)
MX (2) MX2009011856A (es)
WO (1) WO2008131807A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
WO2005072527A2 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011159836A2 (en) 2010-06-15 2011-12-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013148283A1 (en) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP2906255B1 (en) * 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
KR102112892B1 (ko) 2012-11-15 2020-05-19 로슈 이노베이션 센터 코펜하겐 에이/에스 올리고뉴클레오티드 콘쥬게이트
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
MY177989A (en) 2013-01-30 2020-09-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2017067970A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
US11105794B2 (en) 2016-06-17 2021-08-31 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
US11479818B2 (en) 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
EP3339408B1 (en) * 2016-12-22 2020-01-29 The Procter & Gamble Company Fabric softener composition having improved dispensing properties
SG11202001103QA (en) * 2017-08-11 2020-03-30 Agency Science Tech & Res Method for screening splicing variants or events
JP7476101B2 (ja) 2017-12-22 2024-04-30 ロシュ イノベーション センター コペンハーゲン エーエス ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド
CN111448316A (zh) 2017-12-22 2020-07-24 罗氏创新中心哥本哈根有限公司 新的硫代亚磷酰胺
US20200339982A1 (en) 2017-12-22 2020-10-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
WO2020152303A1 (en) 2019-01-25 2020-07-30 F. Hoffmann-La Roche Ag Lipid vesicle for oral drug delivery
KR102470669B1 (ko) * 2022-06-03 2022-11-25 충남대학교 산학협력단 스플라이싱-스위치 올리고뉴클레오티드를 유효성분으로 포함하는 폴리프로모 1 유전자의 스플라이싱 조절용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410324B1 (en) * 2001-04-27 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of tumor necrosis factor receptor 2 expression
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
WO2003070897A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070105807A1 (en) * 2005-11-10 2007-05-10 Sazani Peter L Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease
EP2089521A1 (en) * 2006-02-08 2009-08-19 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease

Also Published As

Publication number Publication date
KR20150139979A (ko) 2015-12-14
CN104278033A (zh) 2015-01-14
JP2010524476A (ja) 2010-07-22
KR20100101050A (ko) 2010-09-16
AU2018200382A1 (en) 2018-02-08
CA3072221A1 (en) 2008-11-06
AU2007352163A1 (en) 2008-11-06
KR20170056032A (ko) 2017-05-22
US20120142759A1 (en) 2012-06-07
CN101889086A (zh) 2010-11-17
HK1150850A1 (en) 2012-01-13
KR101531934B1 (ko) 2015-06-29
JP2014050400A (ja) 2014-03-20
MX346434B (es) 2017-03-21
CA2684724A1 (en) 2008-11-06
EP2147103A2 (en) 2010-01-27
CN101889086B (zh) 2014-07-02
WO2008131807A3 (en) 2009-02-12
HK1205184A1 (en) 2015-12-11
AU2014203220A1 (en) 2014-07-10
AU2019208249A1 (en) 2019-08-15
WO2008131807A2 (en) 2008-11-06
CA3165250A1 (en) 2008-11-06
KR20150036814A (ko) 2015-04-07
AU2016203220A1 (en) 2016-06-09
KR101738655B1 (ko) 2017-05-22
AU2021204434A1 (en) 2021-07-29
EP2147103B1 (en) 2018-12-12
CA2991580A1 (en) 2008-11-06
KR20180082646A (ko) 2018-07-18

Similar Documents

Publication Publication Date Title
MX2009011856A (es) Oligomeros de cambio de division de receptores de la superfamilia tnf y su uso en tratamientos o enfermedades.
MX2008006089A (es) Oligomeros de conmutacion de empalme para los receptores de la super-familia de tnf y su uso en el tratamiento de enfermedades.
Bartel et al. Modulation of NK cell function by genetically coupled C-type lectin-like receptor/ligand pairs encoded in the human natural killer gene complex
JP2011526891A5 (es)
JP2015519891A5 (es)
MX2021009178A (es) Composiciones de oligonucleotidos y metodos de las mismas.
WO2010151671A3 (en) Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
JP2023093644A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
TN2012000393A1 (en) Agonist dr5 binding polypeptides
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
JP2017513469A5 (es)
JP2015523854A5 (es)
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
MX2009008413A (es) Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2009126789A3 (en) Engineering and delivery of therapeutic compositions of freshly isolated cells
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
PT2069324E (pt) Amino piridina fundida como inibidor da hsp90
JP2016520312A5 (es)
JP2017510271A5 (es)
JP2014518619A5 (es)
WO2008109432A3 (en) Therapeutic targeting of interleukins using sirna in neutral liposomes
MX336881B (es) Compuestos heterociclicos triciclicos.

Legal Events

Date Code Title Description
FG Grant or registration